ArticleTherapeutic advances in medical oncology2026
State of the art of perioperative assessment in early non-small-cell lung cancer in Poland in the emerging era of perioperative protocols.
Article in Therapeutic advances in medical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Lung cancer across borders: From molecular epidemiology to precision treatment strategies.Therapeutic advances in medical oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The paradigm of adjuvant treatment for patients in pathological stages II and III of non-small-cell lung cancer has changed toward the adjuvant combination of chemotherapy and immune checkpoint inhibitors, neoadjuvant chemoimmunotherapy, or ultimately periadjuvant chemoimmunotherapy. The introduction of a new standard requires significant changes in preoperative assessment. A real description of its current state in Poland is required, which can form the basis for systemic changes. Objectives: The aim of our study was to analyze the current standards for preoperative assessment in Poland. Design: Observational study. Methods: A comprehensive survey was conducted across seven thoracic surgery centers in Poland, focusing on preoperative pathological examination techniques, imaging methodologies, multidisciplinary team consultations, and the interval between imaging and surgical resection. Results: The survey analyzed data from 459 patients who were operated between January 2024 and October 2024. The most common pathological diagnostic methods were intraoperative frozen section, and preoperative core biopsy. Almost all patients in stages pIA-IIIB had contrast-enhanced computerized tomography (CT) of the chest, positron emission tomography (PET/CT), and bronchoscopy before surgery. In Poland, brain imaging is not a standard part of the preoperative assessment, and brain scans are obtained only exceptionally (pooled median 0% of patients in stages IA-IIIB). The median time between the CT and surgery was 61 days (range 30-90 days), and between PET/CT and surgery 35 days (range 10-66 days). The median time between the surgery and pathological report was 17 days (range 5-30 days). Multidisciplinary tumor boards are organized in the postoperative period for all patients comparing to pooled median 50% in preoperative period. In the vast majority of cases, the expression status of Programmed Death Ligand-1 and next-generation sequencing were carried out only in postoperative samples. Conclusion: Current compliance with perioperative assessment standards in Poland is inadequate. The consequence of this situation may be low availability of perioperative treatment protocols.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.